In praise of studies that use more than one generic preference-based measure

12 July 2019 - Generic preference-based measures of health-related quality of life are widely used as outcome measures in cost-effectiveness and ...

Read more →

Lung cancer survivor wants PHARMAC to fund drugs she received in trial

22 October 2018 - Lung cancer patient Marjolein Baas takes the drug ceritinib, one of six lung cancer treatment drugs the ...

Read more →

Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?

21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions.  ...

Read more →

Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany

13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...

Read more →

Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful

4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...

Read more →

German watchdog calls for direct comparison of cancer immunotherapies

16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...

Read more →

Finding RCTs of new drugs: searches in trial registries require specific adaptations

5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...

Read more →

Statistical and clinical significance

4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...

Read more →

Tackling submission and publication bias

17 July 2017 - Evoniuk and colleagues analysed whether submission and publication bias are based on study outcome. ...

Read more →

NICE to launch new evidence tool for medtech product developers

30 May 2017 - NICE is launching an online tool to help medtech companies get their products to patients faster. ...

Read more →

Addressing bias and conflict of interest among biomedical researchers

2 May 2017 - Bias in research is ubiquitous and the goal of every researcher should be to reduce bias and ...

Read more →

Emerging technology which aims to improve muscle movement is NICE’s 100th medtech innovation briefing

28 March 2017 - NICE’s advice series on new or novel healthcare technology reaches a milestone. ...

Read more →

Defining the non-inferiority margin and analysing non-inferiority: an overview

6 March 2017 - Non-inferiority trials are used to assess whether the effect of a new drug is not worse than ...

Read more →

Big pharma funding biases drug trials in favour of a sponsor's product: review

21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...

Read more →

Pharmaceutical industry financial ties linked to 'positive' outcomes in clinical trials for new drugs

18 January 2017 - A new study has found links between medical researchers' financial ties with pharmaceutical companies and "positive" ...

Read more →